丹生医药技术

Daniu Biotech is a Shanghai-based biotechnology company specializing in the discovery and development of innovative small molecule drugs targeting challenging protein-protein interactions (PPI). Founded in 2021, the company leverages its proprietary Daniu-PPI platform, which integrates artificial intelligence, structural biology, and computational chemistry to identify high-affinity lead compounds for traditionally undruggable targets. The company's primary therapeutic focus is on oncology and immunology, aiming to deliver first-in-class therapies for patients with significant unmet medical needs. Daniu Biotech is backed by prominent investors such as Qiming Venture Partners and is led by a management team with extensive experience in global drug discovery and development.